Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Global Leukemia Therapeutics Market 2012-2016

Global leukemia therapeutics market: 10% CAGR between 2012-2016


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-03-05 15:32:05 - Global Leukemia Therapeutics Market 2012-2016 - a new market research report on companiesandmarkets.com

The Global Leukemia Therapeutics market is to grow at a CAGR of 10 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant increase in the number of cancer patients worldwide. The Global Leukemia Therapeutics market has also been witnessing an increase in the number of mergers and acquisitions. However, the delay in cancer diagnosis could pose a challenge to the growth of this market.

There has been increase in the volume of medical tourism in the APAC region. Patients from all around the world are visiting countries such as China and India for various treatments. Healthcare facilities in the APAC region are improving and there is an excellent range of healthcare providers

 

 

that are offering good-quality treatment for diseases such as cancer and other treatments at low cost. Thus the increasing number of patients going to China and India for cancer treatment is a growing trend that is influencing the healthcare organizations in the region to purchase more therapeutic drugs for the treatment of leukemia.

One of the major factors driving the growth of the Global Leukemia Therapeutics market is the increasing prevalence of cancer patients worldwide. Therapeutic drugs are among the remedies for cancer and hence healthcare organizations across the globe are opting for therapeutic drugs in the treatment of leukemia. However, most of the vendors are focusing on the US market, which is expected to witness a faster growth rate than the global market over the period 2012-2016.

The key vendors dominating this market space are Bristol-Myers Squibb Co., Celgene Corp., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Novartis AG. The other vendors mentioned in the report are Ambit Biosciences Inc., ARIAD Pharmaceuticals Inc., Biogen Idec Inc., Cephalon Inc., Clavis Pharma ASA, Eisai Co. Ltd., ERYTECH Pharma SA, Genmab A/S, Genzyme Corp., Pfizer Inc., Sunesis Pharmaceuticals Inc., Talon Therapeutics Inc., and Teva Pharmaceutical Industries Ltd.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com